We infused six human immunodeficiency virus (HIV)-serostatistically significant. Two subjects continued to have decreased cell-associated viral burden and another subject had positive subjects with autologous CD8
V
tion in a single subject with moderately advanced disease after infusions with a nef-specific CTL clone administered IRAL-SPECIFIC cytotoxic T lymphocytes (CTLs) suppress human immunodeficiency virus (HIV) replication in vitro by direct cytotoxicity and by secretion of soluble with interleukin-2 (IL-2). 15 The efficacy of cellular immunotherapy by adoptive transfactors. [1] [2] [3] [4] [5] The viremia of acute HIV-1 infection resolves coincident with the appearance of HIV-specific CTLs. 6, 7 fer of viral-specific CTLs has been shown in mice infected with leukemogenic retroviruses. [16] [17] [18] In murine adenovirus, Moreover, circulating antiviral CTLs decrease when opportunistic infections begin and the likelihood of progressing to influenza, and lymphocytic choriomeningitis virus (LCMV) infections, the adoptive transfer of viral-specific CTLs also acquired immunodeficiency syndrome (AIDS) increases in patients who lack gag-specific CTL. [8] [9] [10] This evidence, toprevents fatal infection. 19, 20 In scid mouse models reconstituted with human peripheral blood mononuclear cells gether with the rapid course of HIV infection in neonates whose T-cell immunity is immature, suggests that CTLs may (PBMCs), the transfer of CD8 CTL has also been shown to be protective for HIV infection and for lymphoproliferative be important in controlling HIV infection. 11 However, HIV-specific CTLs, which can lyse infected disease caused by Epstein-Barr virus (EBV).
21-23
In humans, adoptive transfer of lymphokine-activated CD4 cells and even uninfected CD4 cells that bind serum gp120, could hasten the decline in CD4 cells during HIV CTLs (LAK cells) or tumor-infiltrating lymphocytes (TILs) has been used to treat malignant melanoma and renal cell infection. Antiviral CTLs might also play a role in the noninfectious pneumonitis or central nervous system manifestacarcinoma. 24 , 25 In at least one patient, the transfer of EBV-specific T-cell lines controlled an established lymphotions of HIV infection. 2, 12, 13 The pathogenic role of antiviral CTLs in lymphocytic choriomeningitis virus and hepatitis B proliferative disease. 26 Infusions of cytomegalovirus (CMV)-specific CD8
/ CTL clones to bone marrow transplantation infections has led some to suggest that HIV-specific CTLs may contribute to the immunodeficiency of HIV infection. 14 patients at risk for CMV disease were well tolerated. CMVspecific cytotoxicity was present after the transfer of as few This concern has been reinforced by the possible deterioraas 3.3 1 10 7 cells/m 2 and CMV-specific CTLs persisted for up to 12 weeks. Moreover, treated patients did not develop 31, 34 up to three peptides that the subject's T cells were determined to
We gave 6 HIV-infected subjects a single infusion of 1 recognize. The peptide-incubated PBMCs were washed once to rebillion autologous T cells enriched for HIV-specific cytolytic move unbound peptide, resuspended in 100 mL of T-cell medium, activity against a variety of HIV epitopes in gp120, gag p17
and added to 1 to 4 1 10 9 cultured T cells at a concentration of 1 and 24, and nef. We found no acute toxicity associated with 1 10 6 /mL. Ten days later, T cells for therapy were separated by the infusion and followed changes in plasma and cell-associFicoll-Hypaque density separation and washed before intravenous ated virus and CD4 / T cells in the recipients for 6 months.
infusion over 1 hour. Before infusion, therapy T cells were assayed for contamination with bacteria by aerobic and anaerobic culture, MATERIALS AND METHODS for mycoplasma by T.C. Rapid Detection System test (Gen-Probe, San Diego, CA), and for endotoxin by Limulus amoeba lysate assay Subjects. Adult HIV-seropositive individuals with CD4 counts (Microbiological Associates, Rockville, MD). One to 2 days before of 100 to 400/mL and no history of AIDS-defining opportunistic infusion, T cells were assayed, using a 51 Cr release assay as in infections or neurologic symptoms were enrolled in January and Lieberman et al, 34 for their ability to lyse autologous B-LCL incuFebruary 1993, after obtaining informed consent. The clinical charbated with the peptides to which they were exposed and to autoloacteristics of the six subjects at the time of treatment (3 to 12 months gous B-LCL infected with HIV LAI env-, pol-, gag-, and lacZ-expressafter enrollment) are shown in Table 1 . All but one had a history ing vaccinia recombinant virus. The sum of the HIV-specific of HIV-related symptoms and two met the 1993 Centers for Disease cytotoxicity (defined as the sum of the specific lysis of nef peptideControl criteria for AIDS. 35 Four subjects were taking antiretroviral incubated targets [corrected for background lysis in the absence of drugs for at least 6 weeks before the infusion with no change in peptide] and the specific lysis of the 3 HIV-vaccinia infected targets antiretroviral drug or dosage during the study.
[after the lysis of the lacZ-vaccinia infected target background was HIV CTL epitope characterization. The HIV peptide epitopes subtracted for each]) was required to be at least 25% at an E:T ratio contained in HIV LAI or SF2 env, gag, rev, tat, and nef recognized of 20:1. T-cell lines were also tested for replicating HIV using a by the CTL of mitogen-stimulated T-cell lines generated from p24 Ag assay of supernatants after coculture with seronegative phyPBMCs were determined for each subject as in Lieberman et al. 34 tohemagglutinin (PHA) lymphoblasts. 36 An epitope was defined if autologous B-lymphoblastoid cell lines Subject evaluation. Subjects were evaluated at two baseline vis-(B-LCL) incubated with peptide were lysed at least 5% more than its (within 10 days of infusion) and at 1, 2, 4, 8, and 24 weeks targets incubated with media at an effector:target (E:T) ratio of 25:1 after therapy using history and physical examination, complete blood in at least two assays if peptide-specific lysis was greater than 10% count with differential and platelet count, serum creatinine level, or in three independent assays if the specific lysis was 5% to 10%.
bilirubin and serum aspartate aminotransferase (SGOT), T-cell subThe characterized epitopes were confirmed by the enrichment for sets, b 2 -microglobulin, quantitative PBMC HIV titer, 37 plasma p24 epitope-specific CTLs after exposure of T-cell lines to peptide. Eight and acid dissociated p24 Ag, 38 and plasma bDNA assay. 39 When to 10 days after exposure to peptide-incubated PBMCs, T-cell lines plasma bDNA assay was below the level of detection, plasma was were tested for cytotoxicity in a 4-hour 51 Cr release assay against autologous peptide-incubated and media-control B-LCL as in Lieassayed for HIV using quantitative reverse transcription-polymerase AID Blood 0029 / 5h3d$$$561 08-12-97 13:28:18 bldas WBS: Blood Dominant CTL epitopes were identified using mitogen-stimulated T-cell lines derived from PBMCs at the time of enrollment (see the Materials and Methods). Up to three dominant epitope peptides were used to selectively expand T cells for infusion.
Abbreviation: ND, not done. * Epitopes used to expand the infused cells are in bold. Epitopes recognized by CTLs are likely to be 8-to 11-aa peptides contained in the larger peptides used for screening. These epitopes, based on the sequences of laboratory isolates of HIV, are in relatively conserved regions of the virus. Patients may also recognize additional epitopes in variable regions of the isolates with which they are infected. Epitopes defined for two overlapping peptides may be contained in the 10-aa overlap region. Amino acid numbering as in Ratner et al. 40 † Data are for 4-hour CTL assay performed at an E:T ratio of 10:1. Targets were either preincubated with HIV peptides (for nef peptides only) or infected with HIV-vaccinia recombinants (see the Materials and Methods). Background lysis of targets preincubated with no peptide or infected with vaccinia-lacZ, respectively, was subtracted for HIV-specific percent cytotoxicity.
‡ Unambiguous tissue typing for the second allele of this patient was not possible. counted as one epitope, the subjects' CTLs recognized bedays before and just before the infusion were averaged to obtain a tween one and nine epitopes. The three peptides that best more stable baseline value. The squared differences between these sensitized target cells for lysis were used for CTL expansion two values were averaged and halved to estimate biologic and assay variability for the CTL activity measures. Changes after 1 week and to treat two individuals whose CTLs recognized more than 24 weeks were tested for significance using paired t-tests.
three epitopes. All cell lines met the infusion criteria (no evidence of RESULTS microbial contamination and ú25% HIV-specific CTL activity at an E:T ratio of 20:1, where HIV-specific cytotoxicity Characteristics of the infused T cells. Peptide epitopes is defined as the sum of the percentage of specific lysis of in HIV env, gag, nef, tat, or rev were recognized by the cell gp160-, RT-, gag-, and nef-expressing targets after subtraclines of six of the first eight subjects studied (Table 2) . 41 The tion of the percentage of specific lysis of control targets), two subjects for whom we could not identify peptide epitopes except for the cell line from subject 226, who had deteriowere not eligible for treatment and were not observed. Because the peptides available for this study derive from laborarated clinically in the 6 months between enrollment and the AID Blood 0029 / 5h3d$$$561 08-12-97 13:28:18 bldas WBS: Blood Cr release assay at an E:T ratio of 20:1. T-cell line () before and (ᮀ) after peptide exposure. For subject 226, the pretherapy T-cell line had lost HIV-specific cytotoxicity and the peptide selection was repeated three times to obtain sufficient antiviral activity to meet the infusion criteria (Û25% HIV-specific cytotoxicity at an E:T ratio of 20:1). The background lysis of autologous B-LCL targets was less than 10%, except for T-cell line 202, for which it was 16%.
time we obtained blood to initiate the T-cell line (Fig 1 and 8% lysis of another at an E:T ratio of 10:1; Fig 1F) . The sum of the HIV-specific cytotoxicity of the infused cells for Table 2 ). His cell line no longer recognized the HIV nef epitopes determined 6 months earlier or any other HIVthe six subjects ranged from 42% to 103% at an E:T ratio of 10:1 (Table 2) . expressing targets, but after repetitive stimulation with two previously recognized nef peptides, we generated a line that Because lysis of peptide-incubated targets may overestimate the lysis of infected targets where antigen processing lysed the nef-presenting targets (20% lysis of 1 nef peptide, AID Blood 0029 / 5h3d$$$561 08-12-97 13:28:18 bldas WBS: Blood and presentation may be limiting, we also calculated the recognized nef epitopes, was only 14%, which would have been below the cutoff for treatment. HIV-specific cytotoxicity against targets infected with the three vaccinia-HIV recombinants, vPE16, vCF21, and
The peptide-selected cell lines infused into four of the five other subjects showed twofold to sixfold enhanced lysis of vDK1. If lysis of only the vaccinia-HIV recombinant targets is taken into account for the T-cell lines infused into the five HIV peptide-bearing targets (Fig 1) . The two gag peptides used to stimulate CTL from subject 203 were able to arm patients who recognized at least one non-nef epitope, the sum of the specific cytotoxicities ranged from 46% to 84% targets for lysis, but they did not appreciably augment cytotoxicity. However, even without enhancement, this subject's (mean, 62% { 15%) at an E:T ratio of 10:1, well above the limits set by the protocol. The sum of the cytotoxicities for T-cell line had sufficient cytotoxicity to meet the criteria for infusion. the T-cell line of the sixth patient (subject 226), who only 
Safety.
No subject had an adverse reaction to the infusion. Blood chemistries, hematologic profile, chest x-ray, and pulmonary function tests were unchanged. No subject developed new symptoms of HIV-1 disease during 6 months of observation, although one subject (216) developed presumed Pneumocystis carinii pneumonia 9 months after the infusion. The plasma and cell-associated viral burden and T-cell counts for all time points for each subject are shown in Fig 2 and are discussed in more detail below.
Effect on viral burden. In all samples, serum p24 antigen level was undetectable and the b 2 -microglobulin level was not elevated. The acid dissociated serum p24 was detectable only in subject 216; it decreased from 171 pg/mL pretherapy to undetectable 8 weeks later to 51 pg/mL at 24 weeks (Fig 3A) . Plasma virus was detectable in four subjects by branched DNA-signal amplification (bDNA) assay and by quantitative RT-PCR assay in the other two subjects. The plasma viral load decreased below the pretherapy mean at weeks 1 and 2 in five of six subjects (Fig 3B) . However, none of the plasma viral changes was greater than threefold. For this assay and other assays of viral burden, threefold changes or greater are considered significant. At all times after the infusion, the mean values for plasma viremia were modestly reduced compared with the baseline means, but the changes were not significant (Table 3 and data not shown).
Viral burden in circulating mononuclear cells was assayed by limiting dilution cultures of PBMCs (Table 3 ). The infectious units per million cells (IUPM) of two baseline values for each subject agreed to within threefold. Five of six subjects had detectable virus before infusion; in two of these (subjects 202 and 216), there were substantial decreases in IUPM, which were sustained for at least 6 months (Fig 2) . In subject 202, the IUPM declined from a mean of 30 before treatment to below the detection threshold (õ0.5 IUPM) at 6 months. In subject 216, who had the highest plasma and cell-associated viral burden, the IUPM decreased to 1% of the pretherapy a mean time of 1 week after the infusion and remained fourfold lower than the pretreatment value at 6 months. Only one subject (204) had a significant increase in IUPM at the end of the study, but the increase was detected only at the last visit. The mean IUPM for all subjects at the end of the study was 57% of the baseline mean (47 { 66 at baseline and 27 { 31 at 24 weeks), but the change was not (Table 3) .
infusion. (A) Acid-dissociated p24 Ag was detectable only in subject
Effect on T-cell counts. One and 2 weeks after infusion,
(B) Plasma bDNA levels decreased in the first 2 weeks for five
the absolute CD4 count of all subjects was equal to or greater of six subjects, but only by small amounts. (C) The absolute CD4 count increased for the first 2 weeks after infusion for all subjects.
than the mean baseline value (Fig 3C) . By 6 months after AID Blood 0029 / 5h3d$$$561 08-12-97 13:28:18 bldas WBS: Blood the infusion, the CD4 count had decreased for 4 subjects to cant (P Å .05), but the overall increase in the sum of HIVspecific activity was not (P Å .06). below the baseline value. The CD4 count of subject 204 increased from a low of 180/mL at infusion to 440/mL 6
The four subjects who had a quantitative increase in antiviral cytotoxicity also recognized a broader range of HIV promonths later. One week after the infusion, the mean CD4 and CD8 counts for all subjects had increased by 11% and teins and peptide epitopes. Bulk CTL cultures from subject 202 recognized HIV gag-expressing targets with more than 9%, respectively, and the CD4/CD8 ratio had increased by 10%. By the end of the study, the mean CD4 count was little 10% specific cytotoxicity within 1 week of the infusion and for the remainder of the study. Subject 214 (and to a lesser changed (up 4%), but the mean CD8 count had increased 11% (Table 3) . extent subjects 203 and 216) developed RT-specific CTL for the first time at later time points. When the peptide epitopes Effect on circulating HIV-specific CTLs. In four of six subjects, an increase in circulating CTL reactivity against in env, gag, and nef were mapped 24 weeks after the initial infusion, five new peptide epitopes were recognized by the HIV env-, gag-, and pol-expressing targets occurred within 1 week after the infusion and was evident 6 months later six subjects (Lieberman, manuscript in preparation). (Fig 4) . The four subjects (202, 203, 204 , and 216) with increased HIV-specific CTLs included the subjects (202 and
DISCUSSION

216) who had a long-term decrease in cell-associated viral
The results of this pilot trial suggest that it is possible to burden and the subject (204) with a sustained increase in infuse HIV-infected subjects with ex vivo-expanded HIVhis CD4 count. The two subjects with reductions in cellspecific CTLs safely. No toxicity was observed after the associated viral burden (202 and 216) also began with twice infusion of T cells targeted against a variety of HIV epitopes as many circulating CD8 / T cells. Their mean baseline CD8 contained in gp120, gag p17 and p24, and nef. No subject counts were 2,339/mL and 2,170/mL, respectively; CD8 deteriorated clinically during our follow-up of 6 months. Our counts for the other subjects ranged from 765 to 1,225/mL. results suggest that antiviral CTLs of whatever specificity The mean anti-gp160, RT, and gag CTL activity for all do not aggravate HIV infection. Although almost no CD4 T subjects increased slightly at 1 week. These increases were cells were infused, the CD4 counts of all subjects increased above the estimated biologic and assay variability (3.6%, during the first few weeks after the CTL infusion. Three 3.3%, and 4.7%, respectively) calculated by comparing the subjects had improvements at 6 months in at least one of assay values obtained just before and 10 days before the the principal study end points: cell-associated virus (subjects infusion, but the changes were not statistically significant 202 and 216), plasma viral load (subject 216), and CD4 (Table 4 ). The mean changes for the whole group were comcount (subject 204). A single infusion of 1 billion T cells parable to the mean changes in anti-gp160 or anti-gag cytoenhanced for anti-HIV cytolytic activity without cytokine toxicity of the subset of subjects treated with T cells targeted support increased circulating viral-specific cytotoxicity in to epitopes in those proteins. The baseline mean sum of the most subjects. Because the infused cells did not bear an percentage of specific cytotoxicity against env-, gag-, and identifying marker, we could not assess whether the in vivo RT-expressing autologous targets was 42% { 15%. The rise in viral-specific CTL activity was due directly to the mean was 60% { 23% 1 week after the infusion and was infused cells. The finding of CTLs against HIV proteins 58% { 20% 6 months later. The mean was also above the that were not recognized above background before treatment baseline at all time points in the study. At 6 months, the increase in RT-specific cytotoxicity was statistically signifisuggests that the infusion may have broadened the CTL AID Blood 0029 / 5h3d$$$561 08-12-97 13:28:18 bldas WBS: Blood Four of six subjects' T-cell lines were expanded in the presence of gag peptides, three were expanded with gp 160 peptides and none were expanded with RT peptides. The anti-HIV CTL activity is defined as the difference between the percentage of specific cytotoxicity against an autologous HIV-expressing target and a lacZ-expressing control target at an E:T ratio of 25:1. The sum of HIV-specific cytotoxicity is the sum of the anti-gp 160, RT, and gag values.
This table gives cross-sectional means and standard deviations for each time point. One subject (226) was missing all week-1 CTL evaluations. The P values give the significance levels for paired comparisons from baseline to the given time point.
* The biologic and assay variability, calculated by comparing the two assays on each subject performed before the infusion, was 4% for anti-gp 160-, 3% for anti-RT-, and 5% for anti-gag-specific cytotoxicity.
† If only subjects receiving T cells enhanced for anti-gp 160 cytotoxicity are analyzed (subjects 202, 204, and 214), anti-gp 160 cytotoxicity was 23% { 8% at baseline, 28% { 7% at week 1, and 28% { 10% at week 24.
‡ If only subjects receiving T cells enhanced for gag cytotoxicity are analyzed (subjects 204, 216, 203, and 214), anti-gag cytotoxicity was 24% { 5% at baseline, 28% { 7% at week 1, and 28% { 11% at week 24.
response to the virus. This effect may protect against viral escape mutants.
We developed polyclonal cell lines that recognize several viral peptides because a highly mutable HIV might readily escape a single or a few CTL clones. Possible HIV CTL escape mutants have been reported in infected patients 42 and in a patient who was infused with a nef-specific CTL clone. 15 Sequencing of viral isolates obtained before and after T-cell infusion in a follow-up study are in progress to determine the extent of escape mutants to polyclonal T-cell therapy.
Viral-specific CTL lines are simpler to prepare than CTL clones, but have some disadvantages for pilot studies compared with clones. The antiviral cytolytic activity/cell of Tcell lines is less than that of T-cell clones. Interpretation of results is less clear because of the heterogeneity of cell lines that include nonspecific CTLs and natural killer cells as well as antiviral CTLs. It is also difficult to determine the halflife of infused polyclonal cells without a marker gene. Marked CMV-specific T cells persisted in allograft recipients express CD25, the IL-2 receptor, although they had other AID Blood 0029 / 5h3d$$$561 08-12-97 13:28:18 bldas WBS: Blood cell surface receptors associated with activated CTLs. This pilot trial did not have the statistical power to demonstrate that CTL therapy is beneficial. Not only was the number of suggests that, at least at the time of infusion, the cells did not depend on IL-2 for function or survival, which may have subjects small, but also they were a heterogeneous group in regards to extent of disease, treatment, and the antiviral allowed them to survive in subjects with defects in CD4 Tcell function.
specificities and potency of the infused cells. If infusion of HIV-specific T cells shows a benefit, further studies will be An HIV-seropositive individual has a high frequency of circulating HIV-specific CTLs estimated to be as much as 1 necessary to determine an optimal number of T cells per infusion, how frequently infusions will need to be adminisin 10,000 lymphocytes. 8 The frequency of potential viralspecific precursor CTLs has been estimated to be much tered, and which patient population will benefit. This pilot trial suggests that infusion of autologous Thigher and may be great enough to be measured in percentages. 31, 33 If there are approximately 10 3 CD8 T cells/mL of cell lines containing CD8 / CTLs against a diversity of HIV peptides is safe and merits further investigation. Multiple blood or 5 billion in circulation, then the pool of circulating antiviral CTL may be anywhere from 5 1 10 5 up to 10 8 infusions or treatment with more or more potent CTLs or together with cytokines might have advantages over the sinpotential precursors. The total body lymphoid compartment of spleen, thymus, and lymph nodes is difficult to estimate gle infusion we administered. but is approximately 100-fold larger than the circulating 
